Biotest AG: Biotest receives approval for new intravenous immunoglobulin Yimmugo® (IgG Next Generation)
EQS-News: Biotest AG
/ Key word(s): Regulatory Approval
Biotest receives approval for new intravenous immunoglobulin Yimmugo® (IgG Next Generation)
"Biotest is expanding its immunoglobulin product portfolio with an innovative new product. Yimmugo® offers patients and physicians another important treatment option whose safety, efficacy and tolerability have been proven in the approval studies," emphasises Dr Jörg Schüttrumpf, Chief Scientific Officer of Biotest AG. "The market launch of Yimmugo® in Germany will start before the end of this year."
Based on the successfully conducted clinical trials, the approval covers the following indications in adults, children and adolescents:
Yimmugo® is the first commercial preparation to be produced in an innovative manufacturing process in the new "Biotest Next Level" production facility at the Dreieich site. The new approval of Yimmugo® thus represents an important milestone on the way to a broader portfolio, greater product availability as well as a more sustainable use of the valuable raw material plasma and Biotest's complete climate neutrality by 2035.
"Our future depends on being more sustainable. That is why we try to optimise the use of natural resources wherever we can," underlines Dirk Neumüller, Chief Sustainability Officer, summaring Biotest's vision.
The approval in Germany was preceded by the recently successfully completed decentralised procedure in Germany and Austria, which Biotest submitted in March 2022. The approval procedure was successfully completed in less than 7 months. Approval in Austria is also imminent. Further approvals in European and non-European countries are planned.
Biotest had already received approvals in recent months to use plasma intermediates from the new plant for the production of the approved products human albumin (Albiomin®) and factor VIII (Haemoctin®). With Fibrinogen and Trimodulin, two new plasma proteins, which are also to be produced in the new facility, are also in an advanced stage of development (phase III).
About Yimmugo® (IgG Next Generation)
Yimmugo® is a newly developed polyvalent immunoglobulin G preparation from human blood plasma for intravenous administration (IVIG). The sugar-free ready-to-use solution is approved for replacement therapy in primary antibody deficiency syndromes and secondary immune deficiency, as well as for immunomodulation in autoimmune diseases such as ITP, GBS, CIDP, MMN and Kawasaki’s disease. Yimmugo® is the first approved product from the new Biotest Next Level production facility. The modern production process stands for highest product quality and an extremely responsible use of resources.
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,100 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.
Dr Monika Buttkereit
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
Preference shares: securities’ ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate
14.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
|Phone:||0 61 03 - 8 01-0|
|Fax:||0 61 03 - 8 01-150|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1486621|
|End of News||EQS News Service|